![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NICOX ANNOUNCES PFIZER'S EXERCISE OF OPTION TO DEVELOP LEAD COMPOUND FROM OPHTHALMOLOGY COLLABORATION
NICOX ANNOUNCES PFIZER'S EXERCISE OF OPTION TO DEVELOP LEAD COMPOUND FROM OPHTHALMOLOGY COLLABORATION
November 22, 2005
NicOx S.A. (Eurolist: NICOX) today announced that Pfizer Inc. has selected a development candidate in its collaboration with NicOx, which is focused on novel nitric oxide-donating compounds in ophthalmology. Accordingly, Pfizer has exercised its option to acquire an exclusive worldwide license to the proprietary NicOx compounds covered by the agreement. NicOx will receive a euro 2M payment from Pfizer.
Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=353091)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct